Sevoflurane

Producers shown on SFDA

(Record date:25/08/2021）

(Quoted from EP website；record date:25/08/2021）

Producer:Shandong New Time Pharmaceutical Co., Ltd. is a member enterprise of Lunan Pharmaceutical Group. It is a national key high-tech enterprise. It was founded on March 23, 2002. It has more than 4000 employees. The overall planning covers an area of 8600 Mu and the planned investment is 10 billion yuan. It is mainly engaged in the R & D and production of traditional Chinese medicine, western medicine, chemical raw materials, preparations, antibiotics, biopharmaceutical and genetic engineering.

The enterprise has established a quality assurance system in line with international quality supervision concepts such as ICH, FDA and EDQM. All dosage forms and varieties have passed the new national GMP certification and won the title of "the best industrial enterprise in China's pharmaceutical R & D product line" for many times. The overall quality management level ranks in the forefront of the same industry in the country.

Staff size:4000-4990 persons

Registered capital:RMB 363.908 million

The predecessor of Hebei Yipin Pharmaceutical Co., Ltd. is a pharmaceutical factory of Hebei Provincial Institute of Pharmaceutical Studies which is established in 1988, it was the first factory in China to manufacturing inhalational anesthetics for general anaesthesia. At the same year, the company was awarded Hebei provincial Excellent New Technology First Prize for “The research and manufacturing technology of inhalational anaesthetics”. 

The company has five production lines right now including water injections, lyophilisation, suspension of liquid (inhalational anesthetic), combination (APIs) and pilot scale production, all five production lines have been certified by GMP. 

Staff size:300-399 persons

Registered capital:RMB 68.68 million

Producer:Hengrui Pharma is a pharmaceutical company engaged in the development and commercialization of innovative and high-quality drugs. We are a well-known supplier of oncology drugs, surgical drugs, and interventional imaging solutions in China. We are the largest pharmaceutical company in China by market value in 2020, with about 70 billion USD market capitalization. We ranked the 21st out of the top 1,000 global pharma firms in 2020. We are the first and only Chinese pharma listed on the Pharmaceutical Innovation Index and Pharmaceutical Invention Index released by IDEA Pharma in 2020.

Innovation is the core of our development strategy. We have 28,000 employees globally, among them over 4,700 being research staffs, including 2,500 staffs with Ph.D. & Master degrees, and more than 400 staffs with overseas background. Fifteen R&D centers were built around the globe and several subsidiaries were established in the US, EU, and Japan. We have 8 innovative products marketed, more than 40 innovative candidates in the R&D stage, about 20 innovative products under clinical development in the US and Australia. 1,151 patent applications were submitted up to this point, with 292 patents granted in China and 410 patents granted in the globe, such as the US, EU, and Japan.

Staff size:About 29000 persons

Registered capital:RMB 6 billion 397 million

For supply and market information, please feel free to contact Mr. Paul, paulzhang@yinuopharmchem.com, WhatsApp: +86 18402846978